Tower Research Capital (TRC)’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $438K | Sell |
2,315
-67
| -3% | -$11.7K | 0.01% | 1003 |
|
|
2025
Q4 | $405K | Buy |
2,382
+1,073
| +82% | +$165K | 0.01% | 949 |
|
|
2025
Q3 | $173K | Sell |
1,309
-118
| -8% | -$14.2K | ﹤0.01% | 1581 |
|
|
2025
Q2 | $151K | Sell |
1,427
-1,114
| -44% | -$121K | ﹤0.01% | 2044 |
|
|
2025
Q1 | $315K | Sell |
2,541
-484
| -16% | -$63.1K | 0.01% | 1111 |
|
|
2024
Q4 | $373K | Buy |
3,025
+2,132
| +239% | +$251K | 0.01% | 1263 |
|
|
2024
Q3 | $99.5K | Sell |
893
-1,978
| -69% | -$217K | ﹤0.01% | 2235 |
|
|
2024
Q2 | $306K | Sell |
2,871
-1,659
| -37% | -$182K | 0.01% | 1744 |
|
|
2024
Q1 | $546K | Buy |
4,530
+963
| +27% | +$118K | 0.01% | 825 |
|
|
2023
Q4 | $439K | Sell |
3,567
-898
| -20% | -$112K | 0.01% | 1473 |
|
|
2023
Q3 | $578K | Sell |
4,465
-2,355
| -35% | -$314K | 0.02% | 790 |
|
|
2023
Q2 | $845K | Buy |
6,820
+4,701
| +222% | +$632K | 0.03% | 615 |
|
|
2023
Q1 | $310K | Sell |
2,119
-95
| -4% | -$14.1K | 0.01% | 1124 |
|
|
2022
Q4 | $353K | Sell |
2,214
-1,208
| -35% | -$177K | 0.01% | 911 |
|
|
2022
Q3 | $456K | Sell |
3,422
-6,008
| -64% | -$914K | 0.01% | 1220 |
|
|
2022
Q2 | $1.47M | Sell |
9,430
-3,072
| -25% | -$473K | 0.03% | 480 |
|
|
2022
Q1 | $1.95M | Buy |
12,502
+2,570
| +26% | +$373K | 0.02% | 580 |
|
|
2021
Q4 | $1.27M | Buy |
9,932
+740
| +8% | +$97.3K | 0.02% | 575 |
|
|
2021
Q3 | $1.2M | Buy |
9,192
+2,241
| +32% | +$339K | 0.03% | 453 |
|
|
2021
Q2 | $1.24M | Sell |
6,951
-3,169
| -31% | -$549K | 0.03% | 519 |
|
|
2021
Q1 | $1.66M | Sell |
10,120
-104
| -1% | -$17.1K | 0.03% | 549 |
|
|
2020
Q4 | $1.69M | Buy |
10,224
+3,848
| +60% | +$573K | 0.05% | 272 |
|
|
2020
Q3 | $909K | Buy |
6,376
+6,222
| +4,040% | +$771K | 0.01% | 1089 |
|
|
2020
Q2 | $17K | Sell |
154
-1,584
| -91% | -$175K | ﹤0.01% | 3759 |
|
|
2020
Q1 | $173K | Buy |
1,738
+1,717
| +8,176% | +$222K | 0.01% | 810 |
|
|
2019
Q4 | $3K | Buy |
+21
| New | +$2.86K | ﹤0.01% | 2926 |
|
|
2019
Q1 | – | Sell |
-1,105
| Closed | -$137K | – | 4036 |
|
|
2018
Q4 | $137K | Buy |
+1,105
| New | +$164K | 0.01% | 831 |
|
|
2018
Q3 | – | Sell |
-113
| Closed | -$19K | – | 4007 |
|
|
2018
Q2 | $19K | Buy |
+113
| New | +$18.5K | ﹤0.01% | 2465 |
|
|
2017
Q4 | – | Sell |
-879
| Closed | -$129K | – | 3758 |
|
|
2017
Q3 | $129K | Buy |
879
+263
| +43% | +$39.8K | 0.01% | 1126 |
|
|
2017
Q2 | $96K | Buy |
+616
| New | +$94.2K | 0.01% | 511 |
|
|
2017
Q1 | – | Sell |
-125
| Closed | -$14K | – | 3485 |
|
|
2016
Q4 | $14K | Buy |
+125
| New | +$13.9K | ﹤0.01% | 2425 |
|
|
2015
Q3 | – | Sell |
-694
| Closed | -$123K | – | 4381 |
|
|
2015
Q2 | $123K | Sell |
694
-1,480
| -68% | -$266K | 0.01% | 650 |
|
|
2015
Q1 | $376K | Buy |
+2,174
| New | +$373K | 0.05% | 208 |
|
|
2014
Q4 | – | Sell |
-1,208
| Closed | -$194K | – | 4344 |
|
|
2014
Q3 | $194K | Buy |
+1,208
| New | +$186K | 0.02% | 538 |
|
|
2014
Q2 | – | Sell |
-855
| Closed | -$118K | – | 4341 |
|
|
2014
Q1 | $118K | Sell |
855
-444
| -34% | -$66.8K | 0.02% | 627 |
|
|
2013
Q4 | $165K | Sell |
1,299
-356
| -22% | -$36.8K | 0.03% | 604 |
|
|
2013
Q3 | $152K | Buy |
1,655
+1,211
| +273% | +$97.7K | 0.02% | 956 |
|
|
2013
Q2 | $31K | Buy |
+444
| New | +$27.1K | ﹤0.01% | 1313 |
|
Other funds holding JAZZ
VPM
VCM
EC
Tower Research Capital (TRC)'s JAZZ Position: Q1 2026 in Review
Tower Research Capital (TRC) reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.8% in Q1 2026, selling an estimated $11.7K and leaving 2,315 shares worth $438K. The position accounts for 0.01% of the portfolio, ranked #1003.
Tower Research Capital (TRC) first reported a position in JAZZ in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.95M in Q1 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Tower Research Capital (TRC) held 2,315 shares of Jazz Pharmaceuticals worth $438K as of Q1 2026.
- Tower Research Capital (TRC) sold 67 Jazz Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
- Jazz Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1003 holding.
- Tower Research Capital (TRC) first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Tower Research Capital (TRC)'s Jazz Pharmaceuticals position peaked at $1.95M in Q1 2022.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.